This content is a clinical-research news roundup rather than a unified theoretical lecture, covering distinct epidemiologic and therapeutic findings in oncology: that hormone replacement therapy formulations are associated with elevated breast cancer risk with the magnitude of risk varying by formulation (combined estrogen-progesterone versus estrogen-only) and by duration and recency of use, with risk attenuating over time after discontinuation; that fractionation schedule (single- versus multi-fraction) of stereotactic body radiotherapy can be compared for non-inferiority in efficacy and toxicity outcomes for oligometastatic disease; and that statin use is associated with reduced colorectal cancer risk, including in patients with inflammatory bowel disease. These illustrate core epidemiologic and clinical-trial methodology — retrospective matched-cohort odds-ratio analysis, randomized non-inferiority comparison, and meta-analysis — within the broader discipline of oncology and cancer epidemiology.
This content is a clinical-research news roundup rather than a unified theoretical lecture, covering distinct epidemiologic and therapeutic findings in oncology: that hormone replacement therapy form…